JERUSALEM--(BUSINESS WIRE)--The Gamida Cell-Teva Joint Venture (JV) announced today that the Data Monitoring Committee (DMC) has independently reviewed data collected from the first 70 patients enrolled in the pivotal registration, Phase III clinical trial of StemEx and has recommended that the JV continue to enroll patients in the StemEx study. This marks the last protocol mandated DMC review of the StemEx study.
